电邮这篇文章 Antihypertensive therapy optimization and endothelial function in patients with gout and chronic urate tubulointerstitial nephritis
- 作者: Lebedeva MV1, Stakhova TY.1, Zaitseva LI2, Selivanova OY.1, Severova MM1
-
隶属关系:
- I. M. Sechenov Moscow Medical Academy
- Clinical Center, I. M. Sechenov Moscow Medical Academy
- 期: 卷 82, 编号 6 (2010)
- 页面: 43-46
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30617
- ID: 30617
如何引用文章
全文:
详细
Subjects and methods. The study enrolled 81 patients aged 39 to 59 years with gout and urate nephropathy. All the patients were diagnosed as having grade 1-2 arterial hypertension. A lower glomerular filtration rate (GFR) was noted in 49.9%; microalbuminuria (MAU) and elevated serum endothelin-1 (ET-1) levels were recorded in all the patients. Combination antihypertensive therapy based on the use of angiotensin-converting enzyme (ACE) inhibitors and/or an angiotensin II receptor blocker (ARB) in combination with calcium channel blockers was performed during 12 months. The time course of changes in blood pressure, the parameters of target organ lesion, and the markers of endothelial dysfunction were monitored.
Results. Before the study, all the examinees were found to have MAU and increased serum ET-1, which are regarded simultaneously as signs of renal lesion and as markers of endothelial function. A combination of an ACE inhibitor or an ARB could diminish albuminuria and reduce ET-1 concentrations, lower systolic and diastolic blood pressure significantly, and increase GFR.
Conclusion. The patients with articular gout and chronic UTIN are observed to have signs of endothelial dysfunction eliminated by combination antihypertensive therapy.
作者简介
M Lebedeva
I. M. Sechenov Moscow Medical Academy
Email: marinaamica@mail.ru
кафедра терапии и профболезней МПФканд. мед. наук, доц; Московская медицинская академия им. И. М. Сеченова; I. M. Sechenov Moscow Medical Academy
T Stakhova
I. M. Sechenov Moscow Medical Academyкафедра терапии и профболезней МПФаспирант; Московская медицинская академия им. И. М. Сеченова; I. M. Sechenov Moscow Medical Academy
L Zaitseva
Clinical Center, I. M. Sechenov Moscow Medical AcademyClinical Center, I. M. Sechenov Moscow Medical Academy
O Selivanova
I. M. Sechenov Moscow Medical Academyкафедра терапии и профболезней МПФзав., кабинет функциональной диагностики клиники нефрологии, внутренних и профессиональных болезней им. Е. М. Тареева; Московская медицинская академия им. И. М. Сеченова; I. M. Sechenov Moscow Medical Academy
M Severova
I. M. Sechenov Moscow Medical Academyкафедра терапии и профболезней МПФаспирант; Московская медицинская академия им. И. М. Сеченова; I. M. Sechenov Moscow Medical Academy
参考
- Feig D. I., Duk-Hee Kang, Johnson R. J. Uric acid and cardiovascular risk. N. Engl. J. Med. 2008; 360: 539-543.
- Forman J. P., Choi H., Curhan G. C. Plasma uric acid level and risk for incident hypertension among men. J. Am. Soc. Nephrol. 2007; 18: 287-292.
- Лебедева М. В., Балкаров И. М., Мухин Н. А. Ранняя диагностика уратного поражения почек. Тер. арх. 1997; 6: 56- 59.
- Шоничев Д. А., Балкаров И. М., Лебедева М. В. Формирование АГ у лиц с нарушением обмена мочевой кислоты. Тер. арх. 1999; 6: 37-40.
- Landmesser U., Drexler H. The clinical significance of endothelial dysfunction. Curr. Opin. Cardiol. 2005; 20 (6): 547- 551.
- Mercuro G., Vitale C., Cerquetani E. et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am. J. Cardiol. 2004; 94 (7): 932-935.
- Kanellis J., Kang D. H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin. Nephrol. 2005; 25: 39-42.
- Российское медицинское общество по артериальной гипертонии - Всероссийское научное общество кардиологов. Диагностика и лечение артериальной гипертензии: Российские рекомендации (третий пересмотр). М.; 2008.
- Mazzone T. Adipose tissue and the vessel wall. Curr. Drug Targets 2007; 8 (11): 1190-1195.
- Мухин Н. А., Моисеев В. С., Кобалава Ж. Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер. арх. 2004; 6: 39-46.
- Remuzzi G., Weening J. J. Albuminuria as early test for vascular disease. Lancet 2005; 365: 556-557.
- Мухин Н. А., Моисеев В. С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестн. РАМН 2003; 11: 50-55.
- Resnik N., Yahav H., Shay-Salit A. et al. Fluid shear stress and the vascular endothelium: for better and for worse. Progr. Biophys. Mol. Biol. 2003; 81 (3): 177-199.
- Mercuro G., Vitale C., Cerquetani E. et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am. J. Cardiol. 2004; 94 (7): 932-935.
- Kanellis J., Kang D. H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin. Nephrol. 2005; 25: 39-42.
- Johnson R. J., Kang D. H., Feig D. et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-1190.
- Kang D. H., Park S. K., Lee I. K., Johnson R. J. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J. Am. Soc. Nephrol. 2005; 16 (12): 3553-3562.
- Чазова И. Е., Ратова Л. Г. Комбинированная терапия артериальной гипертонии. Сердце 2005; 4 (3): 120-126.
- Jameson K., Weber M. A., Bakris G. L. et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
- Alleman Y., Fraile B., Lambert M. et al. Efficacy of the combination of amlodipine and valsartan in patients uncontrolled with monotherapy: the Exforge in Failure after Single Therapy (Ex-FAST) Study. J. Clin. Hypertens. (Greenwich) 2008; 10 (3): 185-194.
补充文件
